Cambridge startup Editas plans to test IPO market for biotechs

Editas Medicine Inc., a Cambridge startup that is developing treatments to modify disease-causing genetic defects, plans to go public in a deal that could test the strength of the market for new biotech stocks.

In a filing Monday with the Securities and Exchange Commission, two-year-old Editas did not specify the sales price range or when it would go public. The filing said the company would offer up to $100 million in stock, a placeholder amount that probably will change as the initial public offering draws closer.

As one of a trio of Cambridge biotech companies competing in the emerging field of gene editing, which seeks to repair defective mutations responsible for about 6,000 genetic diseases, Editas is the kind of hot company that has attracted stock investors over the past few years.